Paolo Tarantino/X
Jun 14, 2025, 17:40
Paolo Tarantino: What Patients Are Eligible for Adjuvant CDK4/6 Inhibitors?
Paolo Tarantino, 2025 Yvonne’s Top Voice’ Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“What patients are eligible for adjuvant CDK4/6i?
We looked at this in ConcertAI: the approval of ribo doubled the patients eligible for adjuvant CDK4/6i (15% -> 30%) and provided an option for 10% of patients with N0 disease, those with the most aggressive cancers.”
Title: Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: a United States Electronic Health Records database analysis
Journal: ESMO Open
Authors: P. Tarantino, H.S. Rugo, G. Curigliano, J.A. O’Shaughnessy, W. Janni, K. Jhaveri, J. Mouabbi, A. Brufsky, E. Hamilton, R. O’Regan, L. Santarsiero, M. Akdere, F. Ye, A. Scotchmer, S.L. Graff
More posts featuring Paolo Tarantino on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 15, 2025, 11:38
Jun 15, 2025, 11:19